Advanced Virgo Plus: Future Perspectives

Membrane Engineering: Future Perspectives

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However, because several randomized Phase III studies testing new multikinase inhibitors failed, sorafenib...

Advanced therapies for the treatment of hemophilia: future perspectives

Monogenic diseases are ideal candidates for treatment by the emerging advanced therapies, which are capable of correcting alterations in protein expression that result from genetic mutation. In hemophilia A and B such alterations affect the activity of coagulation factors VIII and IX, respectively, and are responsible for the development of the disease. Advanced therapies may involve the replac...

Advanced gastric cancer: Current treatment landscape and future perspectives.

Gastric cancer currently ranks fourth in cancer-related mortality worldwide. In the western world, it is most often diagnosed at an advanced stage, after becoming metastatic at distant sites. Patients with advanced disease (locally advanced or metastatic) have a somber prognosis, with a median overall survival of 10-12 mo, and palliative chemotherapy is the mainstay of treatment. In recent year...

Treatment of Advanced Cholangiocarcinoma: Current Status and Future Perspectives

Cholangiocarcinoma (CC) is a tumour with a poor prognosis. The treatment of CC is challenging as the tumour is usually diagnosed late and the treatments are not very effective except when complete surgical resection is possible. However in the majority of cases, surgical resection is not possible and palliation is the mainstay of treatment. Currently chemotherapy combining gemcitabine with a pl...